Isao Fujioka

The EUTOS long‐term survival score predicts disease‐specific mortality and molecular responses among patients with chronic myeloid leukemia in a practice‐based cohort

Eriko Sato, Noriyoshi Iriyama, Michihide Tokuhira et al. · Cancer Medicine · 2020 · 32 citations · Full text

Molecular Responses, Mixed-phenotype Acute Leukemia, Prognosis +18

Features of vascular adverse events in Japanese patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a retrospective study of the CML Cooperative Study Group database

Isao Fujioka, Tomoiku Takaku, Noriyoshi Iriyama et al. · Annals of Hematology · 2018 · 27 citations

Hematological Malignancy, Thrombosis, Chronic Myeloid Leukemia +14

Efficacy and safety of nilotinib therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase

Michihide Tokuhira, Yuta Kimura, Keiji Sugimoto et al. · Medical Oncology · 2018 · 21 citations

Chronic Phase, Hematological Malignancy, Chronic Myeloid Leukemia +8

Incidences and outcomes of therapy-related chronic myeloid leukemia in the era of tyrosine kinase inhibitors: Surveillance of the CML Cooperative Study Group

Noriyoshi Iriyama, Michihide Tokuhira, Tomoiku Takaku et al. · Leukemia Research · 2017 · 18 citations

Hematological Malignancy, Oncology, Hematology +6

Introduction of second-generation tyrosine kinase inhibitors may reduce the prognostic impact of high-risk patients, according to the European treatment and outcome study (EUTOS) score

Eriko Sato, Noriyoshi Iriyama, Michihide Tokuhira et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2017 · 11 citations

Cancer Management, Prognosis, Pathology +16